Tirbanibulin is a microtubule inhibitor indicated for the topical field treatment of actinic keratosis on the face or scalp. It is available as ointment for topical use. MedsAcross supplies Tirbanibulin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
KLISYRI is indicated for the topical field treatment of actinic keratosis on the face or scalp. KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.
Source: US FDA prescribing information
Tirbanibulin is a microtubule inhibitor. The mechanism of action of KLISYRI for the topical treatment of actinic keratosis is unknown.
Source: US FDA prescribing information
For topical use only, not for oral or ophthalmic use. Apply KLISYRI evenly to cover up to 100 cm 2 treatment field on the face or balding scalp once daily for 5 consecutive days using 1 unit-dose packet per application. Wash hands immediately with soap and water after application. Avoid washing and touching the treated area for approximately 8 hours after application of KLISYRI. Following this time, the area may be washed with a mild soap. Avoid transfer of KLISYRI to the periocular area. Avoid application near and around the mouth and lips. For topical use, not for oral or ophthalmic use. Apply KLISYRI to the treatment field on the face or scalp once daily for 5 consecutive days using 1 unit-dose packet per application.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Ophthalmic Adverse Reactions: May cause eye irritation upon ocular exposure. Avoid transfer of the drug into the eyes and to the periocular area. If accidental exposure occurs, flush eyes with water and seek medical care. Local Skin Reactions: Local skin reactions can occur including severe reactions (e.g., vesiculation/pustulation, erosion/ulceration) in the treated area. Avoid use until skin is healed from any previous drug or surgical treatment.
Source: US FDA prescribing information
Most common adverse reactions (incidence ≥2%) are local skin reactions, application site pruritus, and application site pain.
Source: US FDA prescribing information
Store at 20°C-25°C (68°F-77°F), excursions permitted to 15°C-30°C (59°F-86°F). Do not refrigerate or freeze.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Tirbanibulin, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Klisyri 1% ointmentTopical | Almirall | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 1 presentations of Tirbanibulin and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Tirbanibulin, including Klisyri.
Yes. The US FDA first approved Tirbanibulin on 14 December 2020, according to Drugs@FDA.
Yes. Tirbanibulin has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Tirbanibulin is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tirbanibulin is classified under ATC code D06BX03 (Tirbanibulin).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.